Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

133%(4 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_3

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(2)

Detailed Status

Completed3

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (40.0%)

Phase 33 (60.0%)

Trials by Status

completed360%

withdrawn120%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

withdrawnphase_2

Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis

NCT03726788

completedphase_3

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

NCT00876447

completedphase_3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00311376

terminatedphase_2

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00575016

completedphase_3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00461292

Clinical Trials (5)

Showing 5 of 5 trials

NCT03726788Phase 2

Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis

Withdrawn

NCT00876447Phase 3

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Completed

NCT00311376Phase 3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Completed

NCT00575016Phase 2

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Terminated

NCT00461292Phase 3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Completed

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5